<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947956</url>
  </required_header>
  <id_info>
    <org_study_id>MA-HCC-RWS-008</org_study_id>
    <nct_id>NCT04947956</nct_id>
  </id_info>
  <brief_title>Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma in China: a Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary liver cancer is the second most common cause of cancer death in China, and&#xD;
      hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases. The majority&#xD;
      of HCC cases present at an advanced stage, and are thus not amenable to surgery.&#xD;
      Immunotherapies, including PD-1 and PD-L1 inhibitors, alone or combined with other regimens,&#xD;
      have shown encouraging clinical activity in unresectable HCC. Camrelizumab, a humanised&#xD;
      monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and&#xD;
      consequently inhibit the immune escape of tumour cells， which has been approved for the&#xD;
      second-line treatment of advanced HCC. This observational study aims to evaluate the safety&#xD;
      and efficacy of camrelizumab in Chinese unresectable HCC in the real world.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary liver cancer is the second most common cause of cancer death in China, and&#xD;
      hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases. The majority&#xD;
      of HCC cases present at an advanced stage, and are thus not amenable to surgery.&#xD;
      Immunotherapies, including PD-1 and PD-L1 inhibitors, alone or combined with other regimens,&#xD;
      have shown encouraging clinical activity in unresectable HCC. Camrelizumab, a humanised&#xD;
      monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and&#xD;
      consequently inhibit the immune escape of tumour cells，which has been approved for the&#xD;
      second-line treatment of advanced HCC. This multi-center, open-label, observational study&#xD;
      aims to evaluate the safety and efficacy of camrelizumab in Chinese unresectable HCC in the&#xD;
      real world. This study also aims to evaluate the treatment of camrelizumab in subgroups, to&#xD;
      provide information of treatment regimens and efficacy in clinical practice. The anticipated&#xD;
      sample size is 1000, and the camrelizumab-based treatment will be determined by the&#xD;
      investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of treatment-emergent adverse events (TEAE)</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>The incidence of treatment-emergent adverse events (TEAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to ~2 years</time_frame>
    <description>Time to progression</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>The camrelizumab-based treatment will be determined by the investigator.</description>
    <other_name>Apatinib, TACE, Radiotherapy, et al</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Unresectable hepatocellular carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Volunteer to participate in this study and sign an informed consent form; 2. Age ≥&#xD;
             18 years; 3. Hepatocellular carcinoma confirmed/clinically confirmed by&#xD;
             histopathology, cytology or imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Documented pregnant or breastfeeding women;&#xD;
&#xD;
          -  2. Patients who are participating in any interventional trials beyond clinical&#xD;
             practice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jian Zhou, Doctor</last_name>
    <phone>13801914007</phone>
    <email>zhou.jian@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Hu, Doctor</last_name>
    <phone>15821405191</phone>
    <email>hu.jie3@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.</citation>
    <PMID>32112738</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, Wang X, Lan B, Wang X, Xu J, Zhang H, Chi Y, Yang Q, Xu B. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018 Aug;119(5):538-545. doi: 10.1038/s41416-018-0100-3. Epub 2018 May 14.</citation>
    <PMID>29755117</PMID>
  </reference>
  <reference>
    <citation>Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, Wang P, Zhang H, Yang Q, Jiao Y. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clin Cancer Res. 2018 Mar 15;24(6):1296-1304. doi: 10.1158/1078-0432.CCR-17-2439. Epub 2018 Jan 22.</citation>
    <PMID>29358502</PMID>
  </reference>
  <reference>
    <citation>Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z, Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, Ma K, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2021 Feb 15;27(4):1003-1011. doi: 10.1158/1078-0432.CCR-20-2571. Epub 2020 Oct 21.</citation>
    <PMID>33087333</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Jian Zhou</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

